Status:
COMPLETED
Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms
Lead Sponsor:
Fonterra Research Centre
Collaborating Sponsors:
Danisco
Sprim Advanced Life Sciences
Conditions:
Gastrointestinal Symptoms
Eligibility:
All Genders
25-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study was to investigate the dose response effect of Bifidobacterium lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms.
Eligibility Criteria
Inclusion
- healthy males and females aged 25 to 65 years
- stool type 2-4 on the Bristol Stool Chart
- 1 to 3 bowel movements per week
Exclusion
- use of any probiotic product intended to improve gastrointestinal function within the 2 weeks preceding study entry
- major chronic and uncontrolled systemic medical conditions
- severe gastrointestinal conditions known to prolong CTT
- lactose intolerance
- chronic diarrhea
- gastric bypass surgery or lap band insertion for weight loss
- regular laxative use
- pregnant or breast-feeding women
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01171014
Start Date
June 1 2009
End Date
December 1 2009
Last Update
July 28 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.